Table 3.
Multivariate analysis to determine the risk of having a positive COVID-19 PCR test across patients in the SCCAMP study.
| Hazard ratio | Lower 0.95 | Upper 0.95 | P-value | Significance | |
|---|---|---|---|---|---|
| Age: >60 years | 0.59 | 0.31 | 1.09 | .0933 | * |
| 1 year previous medication: high | 0.93 | 0.51 | 1.72 | .8261 | |
| Socio-economic: high | 0.94 | 0.51 | 1.74 | .8442 | |
| 5 years comorbidity QCI > 0 | 0.58 | 0.18 | 1.89 | .3645 | |
| Gender: female | 1.23 | 0.63 | 2.41 | .5376 | |
| Vaccinated | 0.26 | 0.14 | 0.48 | 1.50E-05 | *** |
Summary of the hazard ratios, confidence intervals of the hazard ratios as lower 95% bound and upper 95% bound.
P-value and significance: ***, .001; **, .01; and *, .05; 0.1 across clinical variables age (>60 years).
Recent previous medications (1-year medicines >5).
High socioeconomic score = SMID quintiles ≥4.
High medication comorbidity = prescribed medications in 1 year prior to recruitment >5, comorbidity QCI (Quan–Charlson indices) >0 in 5 years prior to recruitment, gender = Female and vaccination status (at least 2 doses). For full threshold information see Supplemental Methods.